Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Sergi

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Oncology|November 19, 2011
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale studyP Vici, F Giotta, L Di Lauro, et al.
European Review for Medical and Pharmacological Sciences|May 16, 2018
Meta-analyses on intra-aortic balloon pump in cardiogenic shock complicating acute myocardial infarction may provide biased resultsM C Acconcia, Q Caretta, F Romeo, et al.
European Review for Medical and Pharmacological Sciences|October 11, 2019
Effectiveness of the new generation transcatheter aortic valve in the real life studies. Review and meta-analysisM C Acconcia, Q Caretta, L Monzo, et al.
La Clinica Terapeutica|October 2, 2009
Recent advances in the adjuvant treatment of early breast cancerC De Luca, P Vici, S Carpano, et al.
La Clinica Terapeutica|May 3, 2011
[Specificity of action of anticancer agents]P Vici, D Sergi, L Pizzuti, et al.
La Clinica Terapeutica|October 24, 2007
[High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]F Conti, S Carpano, D Sergi, et al.
European Review for Medical and Pharmacological Sciences|July 13, 2019
Meta-analysis of the impact on early and late mortality of TAVI compared to surgical aortic valve replacement in high and low-intermediate surgical risk patientsD Sergi, M C Acconcia, S Muscoli, et al.
La Clinica Terapeutica|January 27, 2009
Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatmentP Vici, G Viola, S Rossi, et al.
La Clinica Terapeutica|January 27, 2009
Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patientsP Vici, G Viola, C Botti, et al.
World Journal of Gastroenterology|August 6, 2008
Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel diseaseLuciana Rigoli, Claudio Romano, Rosario Alberto Caruso, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Oncology|November 19, 2011
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale studyP Vici, F Giotta, L Di Lauro, et al.
European Review for Medical and Pharmacological Sciences|May 16, 2018
Meta-analyses on intra-aortic balloon pump in cardiogenic shock complicating acute myocardial infarction may provide biased resultsM C Acconcia, Q Caretta, F Romeo, et al.
European Review for Medical and Pharmacological Sciences|October 11, 2019
Effectiveness of the new generation transcatheter aortic valve in the real life studies. Review and meta-analysisM C Acconcia, Q Caretta, L Monzo, et al.
La Clinica Terapeutica|October 2, 2009
Recent advances in the adjuvant treatment of early breast cancerC De Luca, P Vici, S Carpano, et al.
La Clinica Terapeutica|May 3, 2011
[Specificity of action of anticancer agents]P Vici, D Sergi, L Pizzuti, et al.
La Clinica Terapeutica|October 24, 2007
[High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]F Conti, S Carpano, D Sergi, et al.
European Review for Medical and Pharmacological Sciences|July 13, 2019
Meta-analysis of the impact on early and late mortality of TAVI compared to surgical aortic valve replacement in high and low-intermediate surgical risk patientsD Sergi, M C Acconcia, S Muscoli, et al.
La Clinica Terapeutica|January 27, 2009
Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatmentP Vici, G Viola, S Rossi, et al.
La Clinica Terapeutica|January 27, 2009
Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patientsP Vici, G Viola, C Botti, et al.
World Journal of Gastroenterology|August 6, 2008
Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel diseaseLuciana Rigoli, Claudio Romano, Rosario Alberto Caruso, et al.
Pageof 4